ESTxENDS Trial- Substudy on Oxidative Stress Induced by Electronic Nicotine Delivery Systems (ENDS) Measured in EBC

NACompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions
Smoking CessationOxidative Stress
Interventions
OTHER

ENDS (vaporizer/e-cig) and smoking cessation counseling

Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.

OTHER

Smoking cessation counseling

Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.

Trial Locations (1)

1011

Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne, Lausanne

All Listed Sponsors
collaborator

University of Lausanne

OTHER

collaborator

University of Geneva, Switzerland

OTHER

collaborator

Swiss National Science Foundation

OTHER

lead

University of Bern

OTHER

NCT03612453 - ESTxENDS Trial- Substudy on Oxidative Stress Induced by Electronic Nicotine Delivery Systems (ENDS) Measured in EBC | Biotech Hunter | Biotech Hunter